New Multiple Sclerosis Vaccine Harmless

by Medindia Content Team on  August 14, 2007 at 4:13 PM General Health News   - G J E 4
New Multiple Sclerosis Vaccine Harmless
The new multiple sclerosis vaccine seems to be harmless and quite valuable as it brings about some valuable changes in such patients. The cause of the disease is still unknown but it seems that the immune system attacks the myelin sheaths that protect nerve cells in the brain and spinal cord.

These immune cells and antibodies recognize and attack specific substances in the myelin, such as myelin basic protein .It has also been seen that Certain multiple sclerosis vaccine small proteins produced by cells that trigger inflammation has a significant role in the event. All this damages the nerve cell's axon, which transmits messages to other neurons.

Amit Bar-Or, M.D., of the Montreal Neurological Institute and colleagues tested a DNA vaccine, BHT-3009, that encodes a full-length human myelin basic protein. Between 2004 and 2006, the researchers administered the vaccine to 30 patients with relapsing-remitting MS [characterized by symptomatic periods and periods of remission] or secondary progressive MS [when symptoms progressively worsen, but there still may be periods of remission].

After one, three, five and nine weeks, participants received intramuscular injections of placebo or BHT-3009 (in doses of .5 milligrams, 1.5 milligrams or 3 milligrams), with or without 80-milligram pills of atorvastatin calcium, a lipid-lowering drug previously shown to be effective in autoimmune conditions. After 13 weeks, participants who initially received placebo received four injections of BHT-3009.

Magnetic resonance imaging (MRI) and other safety evaluations were performed at the beginning of the study, and again after five, nine, 13, 26, 38 and 50 weeks. "BHT-3009 was safe and well tolerated, provided favorable trends on brain MRI and produced beneficial antigen-specific immune changes," the authors write.

These changes included a reduction in the number of cytokine-producing CD4+ T cells (a type of white blood cell) specifically targeting myelin proteins. This reduction was found in the blood as well as in the cerebrospinal fluid of three patients who voluntarily underwent lumbar puncture after completing the course of BHT-3009.

Atorvastatin did not appear to provide additional benefit."There were no increases in clinical relapses, disability, drug-associated laboratory abnormalities, adverse events or the number and volume of contrast-enhancing [visible on MRI] lesions on brain MRI with BHT-3009 treatment compared with placebo," the authors write. "In fact, there was a trend toward a decrease in the number and volume of contrast-enhancing lesions in the brain in patients treated with BHT-3009 compared with placebo."

Based on these results, a phase 2b trial—a randomized clinical trial in approximately 290 patients—of BHT-3009 is already under way. "If successful in MS, antigen-specific DNA vaccines can be developed for prevention or treatment of related diseases, such as type 1 diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis and myasthenia gravis," the authors conclude.

Source: Eurekalert

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
Could somebody tell me if it’s possible to buy this vaccine? And where?
guest Tuesday, August 28, 2007
From where I can Buy the Vaccine
guest Sunday, August 19, 2007

You May Also Like

View All